This effect is similar to that observed in our published study with early pancreatic cancer.11 DCLK1 expression was unchanged in all other treatment groups, with the exception of the triple therapy group, where it was significantly reduced compared to the gemcitabine-alone group. Here, DCLK1 is linked to familial pancreatic carcinoma.